Novo Nordisk says Victoza helps lower heart risks

COPENHAGEN Novo Nordisk said on Friday the results from a trial showed that its Victoza diabetes drug significantly reduced the risks of major adverse cardiovascular events.

“People with type 2 diabetes generally have a higher risk of experiencing major adverse cardiovascular events. That’s why we are very excited about the results from LEADER (trial), which showed that Victoza … also reduces their risk of major adverse cardiovascular events,” Novo’s Chief Science Officer Mads Krogsgaard Thomsen said.

Novo Nordisk’s shares jumped as much as 7 percent in the minutes after the announcement.

(Reporting by Sabina Zawadzki; Editing by Elaine Hardcastle)

comments powered by Disqus